The Immunohistochemistry (IHC) market is valued at USD 1.9 billion in 2021 and is poised to grow at a significant CAGR of 9.2% over 2022–2028. Since personalized medicine has shown to be quite successful in treating non-small-cell lung cancer patients, its use is anticipated to rise. By providing the most thorough and precise histological subtyping of tumors feasible, immunohistochemistry techniques enable this method of treatment decision-making (supported by predictive immunohistochemistry and the assessment of relevant biomarkers)